[HTML][HTML] Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab
…, E Mogalian, C Tipple, A Peppercorn… - … England Journal of …, 2021 - Mass Medical Soc
Background Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization
or death in older patients and those with underlying conditions. Sotrovimab is a pan-…
or death in older patients and those with underlying conditions. Sotrovimab is a pan-…
Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial
…, S Parra, JE Sager, D Austin, A Peppercorn… - Jama, 2022 - jamanetwork.com
Importance Older patients and those with comorbidities who are infected with SARS-CoV-2
may be at increased risk of hospitalization and death. Sotrovimab is a neutralizing antibody …
may be at increased risk of hospitalization and death. Sotrovimab is a neutralizing antibody …
Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 …
…, E Purdy, S Chen, I Song, A Peppercorn… - JAIDS Journal of …, 2013 - journals.lww.com
Background: Cotreatment of tuberculosis (TB) and HIV among coinfected patients is now the
standard of care. Rifampin (RIF) is a standard part of TB treatment but is a potent inducer of …
standard of care. Rifampin (RIF) is a standard part of TB treatment but is a potent inducer of …
Preventing healthcare-associated Aspergillus infections: review of recent CDC/HICPAC recommendations
DJ Weber, A Peppercorn, MB Miller… - Medical …, 2009 - academic.oup.com
Aspergillus spp. are ubiquitous environmental fungi that are increasingly recognized as a
cause of severe illness and mortality in immunocompromised patients. More than 60 outbreaks …
cause of severe illness and mortality in immunocompromised patients. More than 60 outbreaks …
A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para‐aminohippurate clearance in healthy subjects
…, S Chen, I Song, A Peppercorn… - British journal of …, 2013 - Wiley Online Library
Aim Dolutegravir ( DTG ; S / GSK 1349572) is under clinical development as a once daily,
unboosted integrase inhibitor for the treatment of HIV infection. The effect of DTG on …
unboosted integrase inhibitor for the treatment of HIV infection. The effect of DTG on …
In vivo induced antigen technology (IVIAT)
SM Rollins, A Peppercorn, L Hang… - Cellular …, 2005 - Wiley Online Library
In vivo induced antigen technology (IVIAT) is a technique that identifies pathogen antigens
that are immunogenic and expressed in vivo during human infection. IVIAT is complementary …
that are immunogenic and expressed in vivo during human infection. IVIAT is complementary …
Increasing US rates of endocarditis with Staphylococcus aureus: 1999-2008
…, SC Stearns, AF Peppercorn… - Archives of internal …, 2012 - jamanetwork.com
… Critical revision of the manuscript for important intellectual content: Federspiel, Stearns,
Peppercorn, and Fowler. Statistical analysis: Federspiel and Stearns. Study supervision …
Peppercorn, and Fowler. Statistical analysis: Federspiel and Stearns. Study supervision …
Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir
…, S Chen, P Patel, T Wajima, A Peppercorn… - Antimicrobial agents …, 2012 - Am Soc Microbiol
Healthy subjects received dolutegravir at 50 mg in a single-dose crossover study while they
were in the fasted state or with low-, moderate-, or high-fat meals. Food increased …
were in the fasted state or with low-, moderate-, or high-fat meals. Food increased …
Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial
…, HA Watson, PJ Yates, AF Peppercorn - The Lancet …, 2017 - thelancet.com
Background Neuraminidase inhibitors are effective for the treatment of acute uncomplicated
influenza. However, there is an unmet need for intravenous treatment for patients admitted …
influenza. However, there is an unmet need for intravenous treatment for patients admitted …
Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers
…, Y Lou, S Chen, T Wajima, A Peppercorn… - Journal of …, 2011 - academic.oup.com
Objectives To evaluate the effect of pH-altering agents on S/GSK1349572 exposure in
healthy subjects. Methods S/GSK1349572 is an unboosted, once-daily, next-generation HIV …
healthy subjects. Methods S/GSK1349572 is an unboosted, once-daily, next-generation HIV …
